INDV News & Events

Indivior Pharmaceuticals announced results from two real-world evidence studies showing that adherence to extended-release buprenorphine, marketed as Sublocade, is associated with lower relapse risk and reduced healthcare utilization among patients with opioid use disorder. One analysis of 3,400 patients found those adherent to the treatment were 3.5 to 8.1 times less likely to return to opioid use compared to non-adherent patients. A second study demonstrated a 62% reduction in bacteremia incidence compared to patients receiving daily oral buprenorphine, as well as significantly fewer inpatient and emergency department visits.

Indivior announced that it has entered into a $175M accelerated share repurchase agreement with Barclays. The ASR will be executed under Indivior's existing $400M share repurchase program previously authorized by the company's board of directors. Under the ASR agreement, Indivior will make an upfront payment of $175M to Barclays and expects to receive an initial delivery of 3,717,473 shares promptly following execution. The final number of shares repurchased will be determined based on the volume weighted average price of Indivior's common stock during the term of the ASR, less a discount. Final settlement is expected to occur no later than the end of June. Indivior does not expect the ASR to impact its previously issued financial guidance. The remaining $100M under the share repurchase authorization may be used for additional repurchases from time to time, subject to market conditions and other factors. Repurchases may be made through open market transactions, privately negotiated transactions, or other methods permitted under applicable law.

Reports Q1 revenue $317M, consensus $272.84M. "We are encouraged by our first quarter results, which reflect the progress we are making against Phase II of the Indivior Action Agenda - Accelerate," said Joe Ciaffoni, Chief Executive Officer. "Year-over-year we accelerated SUBLOCADE net revenue and dispense unit growth and grew adjusted EBITDA and cash at an even faster rate while executing on our capital deployment strategy. We remain focused on accelerating SUBLOCADE dispense unit growth, growing our bottom line at a significantly faster rate, and strategically deploying capital as we earn our way to Phase III of the Indivior Action Agenda - Breakout - which we are on track to enter in the second half of 2026."

Consensus $1.16B. Raises FY26 adjusted EBITDA view to $620M-$660M from $535M-$575M. Backs FY26 operating expenses view $430M-$450M. "Strong SUBLOCADE performance in the first quarter led us to raise our 2026 financial guidance," said Ryan Preblick, Chief Financial Officer. "We now expect 2026 total SUBLOCADE net revenue growth of 13% year-over-year and adjusted EBITDA growth of 50% year-over-year at the midpoint of our guidance ranges. We strengthened our financial position with the completion of a $500 million convertible senior notes offering and returned capital to our shareholders through the opportunistic repurchase of $125 million in shares during the quarter. We are committed to creating long-term shareholder value as we advance the Indivior Action Agenda."